These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 36814185)

  • 21. Colorectal Cancer Screening by Fecal Immunochemical Tests (FIT): Considerations on Sampling and Markers (Hb and Hb/Hp Complex) of Fecal Occult Blood (FOB).
    Syrjänen K; Eskelinen M; Meklin J; Hendolin P; Eskelinen M; Suovaniemi O
    Anticancer Res; 2024 Apr; 44(4):1513-1523. PubMed ID: 38537972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the utility and acceptability of Faecal immunochemical testing (FIT) as a novel intervention for the improvement of colorectal Cancer (CRC) surveillance in individuals with lynch syndrome (FIT for lynch study): a single-arm, prospective, multi-centre, non-randomised study.
    Lincoln A; Benton S; Piggott C; North BV; Rigney J; Young C; Quirke P; Sasieni P; Monahan KJ
    BMC Cancer; 2022 Nov; 22(1):1144. PubMed ID: 36344941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A digital intake tool to avert outpatient visits in a FIT-based colorectal cancer screening population: study protocol of a multicentre, prospective non-randomized trial - the DIT-trial.
    Marijnissen FE; de Jonge PJF; Erler NS; Ismail SY; Lansdorp-Vogelaar I; Spaander MCW
    BMC Gastroenterol; 2024 Jan; 24(1):38. PubMed ID: 38238726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of time to colonoscopy after a positive fecal test result and fecal hemoglobin concentration with risk of advanced colorectal neoplasia.
    Kim NH; Lim JW; Kim S; Lim JY; Kim W; Park JH; Park DI; Sohn CI; Jung YS
    Dig Liver Dis; 2019 Apr; 51(4):589-594. PubMed ID: 30733186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening.
    Alvarez-Urturi C; Andreu M; Hernandez C; Perez-Riquelme F; Carballo F; Ono A; Cruzado J; Cubiella J; Hernandez V; Mao CG; Perez E; Salas D; Andrés M; Bujanda L; Portillo I; Sarasqueta C; Quintero E; Morillas JD; Lanas A; Sostres C; Augé JM; Castells A; Bessa X;
    Dig Liver Dis; 2016 May; 48(5):542-551. PubMed ID: 26936343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study).
    Pilonis ND; Bugajski M; Wieszczy P; Rupinski M; Pisera M; Pawlak E; Regula J; Kaminski MF
    Gastroenterology; 2021 Mar; 160(4):1097-1105. PubMed ID: 33307024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FIT for purpose: study protocol for a randomized controlled trial to personalize surveillance colonoscopy for individuals at elevated risk of colorectal cancer.
    Winter JM; Cornthwaite KJ; Young GP; Wilson C; Chen G; Woodman R; Coats M; Fraser R; Cock C; Bampton P; Symonds EL
    Int J Colorectal Dis; 2023 Jul; 38(1):201. PubMed ID: 37490150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal Cancer Screening Decision Based on Predicted Risk: Protocol for a Pilot Randomized Controlled Trial.
    Plys E; Bulliard JL; Chaouch A; Durand MA; van Duuren LA; Brändle K; Auer R; Froehlich F; Lansdorp-Vogelaar I; Corley DA; Selby K
    JMIR Res Protoc; 2023 Sep; 12():e46865. PubMed ID: 37676720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gender-specific cut-off levels in colorectal cancer screening with fecal immunochemical test: A population-based study of colonoscopy findings and costs.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2021 Dec; 28(4):439-447. PubMed ID: 34106777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple Negative Fecal Immunochemical Tests Reduce Risk of Advanced Neoplasia in a Colonoscopy Surveillance Program.
    Wassie MM; Young GP; Winter JM; Cock C; Bampton P; Rahman M; Heddle R; Fraser R; Meng R; Symonds EL
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2389-2398.e2. PubMed ID: 36610499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.
    Gupta S; Halm EA; Rockey DC; Hammons M; Koch M; Carter E; Valdez L; Tong L; Ahn C; Kashner M; Argenbright K; Tiro J; Geng Z; Pruitt S; Skinner CS
    JAMA Intern Med; 2013 Oct; 173(18):1725-32. PubMed ID: 23921906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
    Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
    United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
    Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
    Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round.
    Digby J; Fraser CG; Carey FA; Diament RH; Balsitis M; Steele RJ
    J Med Screen; 2017 Jun; 24(2):62-68. PubMed ID: 27370211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.